Skip Navigation


Human Molecular Genetics Advance Access originally published online on July 13, 2005
Human Molecular Genetics 2005 14(16):2459-2468; doi:10.1093/hmg/ddi246
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrowOA All Versions of this Article:
14/16/2459    most recent
ddi246v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Google Scholar
Right arrow Articles by Agrawal, S.
Right arrow Articles by Eng, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agrawal, S.
Right arrow Articles by Eng, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact: journals.permissions@oupjournals.org

Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN

Shipra Agrawal1,2, Robert Pilarski1,3 and Charis Eng1,2,3,4,5,*

1Clinical Cancer Genetics Program, Human Cancer Genetics Program, Comprehensive Cancer Center, 2Department of Molecular Virology, Immunology and Medical Genetics and 3Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA, 4Genomic Medicine Institute, Cleveland Clinic Lerner College of Medicine, Department of Genetics, Case Western Reserve University, Cleveland, OH, USA and 5Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK

* To whom correspondence should be addressed at: Genomic Medicine Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, No. NE-40, Cleveland, OH 44195, USA. Tel: +1 216 444 3440; Email: engc{at}ccf.org or spsmce{at}netscape.net

Received May 17, 2005; Accepted July 5, 2005

PTEN, encoding a dual phosphatase tumor suppressor, is mutated in 85 and 65% of individuals with Cowden syndrome (CS) and Bannayan–Riley–Ruvalcaba syndrome (BRRS), respectively. Approximately 23 germline mutations in putative splice sites have been published, but resulting downstream outcome data are limited. We determined splicing defects in PTEN in 40 germline PTEN mutation positive cases and 33 mutation negative cases with classic CS, BRRS and CS- or BRRS-like features. Altered splicing was observed in 4/40 mutation positive probands and 2/33 mutation negative probands. We then sought to characterize the transcriptional and biochemical outcomes of the five distinct splice-site mutations, which led to the skipping of exon 3, 4 or 6. Two mutation negative BRRS patients also showed exon 3 skipping, and later, genomic sequencing revealed a mutation deep in intron 2. The splice-site mutations leading to the deletions of exon 3, 4 or 6 resulted in reduced dual phosphatase activities of PTEN. Deletion of exon 4 was associated with severely reduced lipid phosphatase activity, whereas exon 3 skipping resulted in markedly reduced protein phosphatase activity. In addition, exon 3 deleted transcript and protein were stable and localized to the nucleus more efficiently than the wild-type PTEN. In contrast, exon 4 skipping resulted in unstable transcripts and severely truncated unstable PTEN protein lacking its phosphatase domain. We have not only described for the first time, the effect of a deep intronic/branch-site mutation on exon skipping in PTEN but also found that different splice-site mutations resulting in the deletion of different exons lead to distinct outcomes.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. Ghosh, H. Kuppusamy, and L. M. Pilarski
Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein: A POTENTIAL MECHANISM PROMOTING HUMAN CANCER
J. Biol. Chem., July 10, 2009; 284(28): 18840 - 18850.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Adamia, A. A. Reichert, H. Kuppusamy, J. Kriangkum, A. Ghosh, J. J. Hodges, P. M. Pilarski, S. P. Treon, M. J. Mant, T. Reiman, et al.
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia
Blood, December 15, 2008; 112(13): 5111 - 5121.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
T. Tamguney and D. Stokoe
New insights into PTEN
J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Agrawal and C. Eng
Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer
Hum. Mol. Genet., March 1, 2006; 15(5): 777 - 787.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Weber and C. Eng
Editorial: Germline Variants within RET: Clinical Utility or Scientific Playtoy?
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6334 - 6336.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.